Operator
Good morning, and welcome to today s program. My name is Maria, and I ll be your conference operator. At this time, I d like to welcome everyone to ANI Pharmaceuticals Fourth Quarter and-Year End 2020 Earnings Results and Business Update Call.
[Operator Instructions] As a reminder, this conference call is being recorded today, March 9th, 2021. It s now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for ANI Pharmaceuticals. Please go ahead.
Lisa M. Wilson
Investor Relations
Thank you, Maria. Welcome to ANI Pharmaceuticals Q4 2020 Earnings Results Call. This is Lisa Wilson of In-Site Communications, Investor Relations for ANI.
Chad
United-states
Canada
New-jersey
America
Nikhil-lalwani
Lisam-wilson
Dana-flanders-guggenheim
Lisa-wilson
Raymond-james
Elliot-wilbur-raymond-james
Brandon-folkes-cantor-fitzgerald
Senior Editor
ANI is introducing aminocaproic acid tablets in a dosage strength of 500 mg, following approval by the Food and Drug Administration.
Aminocaproic acid tablets have a market value of approximately $12.7 million, according to IQVIA. This is ANI’s seventh generic product launch in 2020 and reaffirms our commitment to increasing the pace of market introductions for our products. This important therapeutic is one of the pipeline generic products we acquired from Amerigen Pharmaceuticals earlier this year. I congratulate our team on this achievement and look forward to additional ANI product launches in the near future, as we focus on realizing the full potential of our product portfolio,” said Nikhil Lalwani, president and CEO.
Nikhil-lalwani
Amerigen-pharmaceuticals
Drug-administration
நிகில்-லல்வானி
அமெரிகேன்-மருந்துகள்